Write For Us

The Science Behind Aduhelm, a Controversial New Alzheimer’s Drug | WSJ

Sponsored Post Vitamin D2 Canada Persia
74 Views
Published
Biogen’s Aduhelm is the first approved treatment for early stage Alzheimer’s patients that may be able to slow the disease. WSJ explains how the drug interacts with brain cells, and why some doctors aren’t ready to prescribe it yet. Illustration: Jacob Reynolds

More from the Wall Street Journal:
Visit WSJ.com: http://www.wsj.com
Visit the WSJ Video Center: https://wsj.com/video

On Facebook: https://www.facebook.com/pg/wsj/videos/
On Twitter: https://twitter.com/WSJ
On Snapchat: https://on.wsj.com/2ratjSM

#Aduhelm #Alzheimers #WSJ
Category
Television
Tags
aduhelm, fda, alzheimer's
Sign in or sign up to post comments.
Be the first to comment